Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Despite high enthusiasm, early attempts to develop clinical treatments based on animal research with neurotrophins were not successful. Here we survey clinical trials with neurotrophins, compared with neurotrophic factors of other gene families, and delineate the most likely reasons for their failure. We then suggest improved methods for regulated local supply of NTs to specific populations of neurons and discuss future therapeutic procedures evolving from the more detailed knowledge of the signal transduction pathways activated by neurotrophins via their receptors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since the discovery of BDNF and its receptor TrkB, efforts have been made to use BDNF as a therapeutic agent for neuropsychiatric disorders or to develop small-molecule pharmaceuticals that could increase the production of BDNF or activate TrkB in brain (for review, see99,100), and these efforts are still ongoing101.”
From Neuronal plasticity and neurotrophic factors in drug responses (2017) · cites this paper as [99]
In the citing paper
“A lack of methods for effectively and safely delivering growth factors to the nervous system over sustained time periods has been a major factor limiting their translational testing32.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [32]
Citations
Cites
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“New, therapeutically interesting perspectives evolved from the observation that physical exercise evokes a marked increase in BDNF levels in the rat brain, in particular in the hippocampus and cerebral corte”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundNEUROTROPHINS AND SYNAPTIC PLASTICITY
McAllister, A. K., Katz, L. C., & Lo, D. C. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.295 · Cited by 1,337 · cited 1×
“This decisive statement can be made because NTs, besides regulating survival, differentiation and maintenance of neuron-specific characteristics (for example, neurotransmitters and neuropeptides), also are important in modulating activity-dependent neuronal plasticity, essential for the functional and structural refin…”
BackgroundNerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284 · cited 1×
“Trks are transmembrane tyrosine kinase receptors with conserved intracellular domains mediating relatively well-characterized signal transduction pathway”
BackgroundKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“Although (unregulated) overexpression of neurotrophic molecules by viral vectors has already provided encouraging result”
BackgroundHuang, Z. J., Kirkwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., & Tonegawa, S. (1999) · Cell · doi:10.1016/s0092-8674(00)81509-3 · Cited by 1,198 · cited 1×
“For the treatment of neurons that are themselves directly involved in the formation of neuronal circuits, modified in a refined manner by neuronal activity, the local overexpression of NTs could result in functional disturbances, as for example demonstrated in the visual cortex by the local transgenic overexpression o…”
BackgroundHANDBOOK OF EXPERIMENTAL PHARMACOLOGY
Reichlin, S. (1969) · The American Journal of The Medical Sciences · doi:10.1097/00000441-196911000-00008 · Cited by 1,134
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system
Bibel, M., & Barde, Y.-A. (2000) · Genes & Development · doi:10.1101/gad.841400 · Cited by 1,065
Fischer, W., Wictorin, K., Björklund, A., Williams, L. R., Varon, S., & Gage, F. H. (1987) · Nature · doi:10.1038/329065a0 · Cited by 1,024
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Anthony Altar, C., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 788 · cited 1×
“Other members of the NT family were linked to a much broader spectrum of biological action”
Background
Research works printed but not linked: 1
- Lowenstein, P.R. & Enquist, L.W. Protocols for Gene Transfer in Neuroscience (Wiley, Chichester, UK, 1996).
Cited by
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Miranda, M., Morici, J. F., Zanoni, M. B., & Bekinschtein, P. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00363 · Cited by 1,416
“Moreover, gene therapy and BDNF mimetic strategies came across many negative side effects that led to their abandonment (Thoenen and Sendtner, 2002).”
BackgroundNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034
Thorne, R. G., Pronk, G. J., Padmanabhan, V., & Frey, W. H. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.029 · Cited by 958
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone
Jang, S.-W., Liu, X., Yepes, M., Shepherd, K. R., Miller, G. W., Liu, Y., Wilson, W. D., Xiao, G., Blanchi, B., Sun, Y. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913572107 · Cited by 686
“Because of their neurotrophic activities in promoting neuronal survival and preventing neurodegeneration, neurotrophins and their receptors are targets for therapeutic intervention in neurodegeneration (18, 19).”
BackgroundNeurotrophin signalling in health and disease
Chao, M. V., Rajagopal, R., & Lee, F. S. (2006) · Clinical Science · doi:10.1042/cs20050163 · Cited by 625
Almeida, R. D., Manadas, B. J., Melo, C. V., Gomes, J. R., Mendes, C. S., Grãos, M. M., Carvalho, R. F., Carvalho, A. P., & Duarte, C. B. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401662 · Cited by 583
“Therefore, there is currently an active search for delivery strategies of neurotrophic factors and for neurotrophic factor mimetics.(82,83) A strategy that could be”
Duan, X., Qiao, M., Bei, F., Kim, I.-J., He, Z., & Sanes, J. R. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.017 · Cited by 523
“Second, soluble protein therapeutics are clearly promising for treatment of a variety of neural injuries and neurological diseases (Thoenen and Sendtner, 2002).”
Storkebaum, E., Lambrechts, D., Dewerchin, M., Moreno-Murciano, M.-P., Appelmans, S., Oh, H., Van Damme, P., Rutten, B., Man, W. Y., De Mol, M., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1360 · Cited by 494
BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia
Baker-Herman, T. L., Fuller, D. D., Bavis, R. W., Zabka, A. G., Golder, F. J., Doperalski, N. J., Johnson, R. A., Watters, J. J., & Mitchell, G. S. (2004) · Nature Neuroscience · doi:10.1038/nn1166 · Cited by 484
“Most attempts at therapeutic administration of exogenous neurotrophins to date have faile”
BackgroundThe role of neurotrophic factors in nerve regeneration
Gordon, T. (2009) · Neurosurgical Focus · doi:10.3171/foc.2009.26.2.e3 · Cited by 376
Cell Signaling and the Genesis of Neuropathic Pain
Ji, R.-R., & Strichartz, G. (2004) · Science's STKE · doi:10.1126/stke.2522004re14 · Cited by 371
Variant BDNF (Val66Met) impact on brain structure and function
BATH, K. G., & LEE, F. S. (2006) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.6.1.79 · Cited by 330
“As a result, neurotrophins have been implicated in the pathophysiology of a wide variety of neurodegenerative disorders and have been considered as a therapeutic strategy (Thoenen & Sendtner, 2002).”
BackgroundNeurobiology of local and intercellular BDNF signaling
Sasi, M., Vignoli, B., Canossa, M., & Blum, R. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-1964-4 · Cited by 324
“Therefore, much attention has been given to BDNF because specific interference with BDNF-related signaling is regarded as a leading strategy to stimulate neuronal and synaptic plasticity for potential protective and functionally restorative treatments for neurological and psychiatric disorders [97, 116, 152].”
BackgroundLongo, F. M., & Massa, S. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4024 · Cited by 298
Molecular basis of plasticity in the visual cortex
Berardi, N., Pizzorusso, T., Ratto, G. M., & Maffei, L. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00168-1 · Cited by 288
Neuronal plasticity and neurotrophic factors in drug responses
Castrén, E., & Antila, H. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.61 · Cited by 284
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Acceleration of Visual System Development by Environmental Enrichment
Cancedda, L., Putignano, E., Sale, A., Viegi, A., Berardi, N., & Maffei, L. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0845-04.2004 · Cited by 277
“…of other factors that are potentially important for visual system development (neurotrophins, signal transduction molecules, NMDA receptors, GAD 65, CREB, and many others) (Molteni et al., 2002) and, in particular, increases IGF-I expression (Carro et al., 2000; Thoenen and Sendtner, 2002).”
BackgroundInfluentialNeurotrophin signalling: novel insights into mechanisms and pathophysiology
Mitre, M., Mariga, A., & Chao, M. V. (2017) · Clinical Science · doi:10.1042/cs20160044 · Cited by 263
“Another challenge is to regulate the amounts of trophic factor, as high concentrations of BDNF can cause the down-regulation of TrkB receptors, as has been reported in motor neuron clinical trials [57].”
BackgroundTrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders
Gupta, V., You, Y., Gupta, V., Klistorner, A., & Graham, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510122 · Cited by 258
“exogenous neurotrophin administration is the cross-activation of nociceptors either directly or through p75NTR and also inducing inflammation [115,116].”
BackgroundLladó, J., Haenggeli, C., Maragakis, N. J., Snyder, E. Y., & Rothstein, J. D. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.07.010 · Cited by 207
“The transplantation of NSCs, especially engineered NSCs, may offer several advantages to the conventional therapeutics: They may provide a constant and physiological source of neurotrophic factors allowing for a more optimal and long-term effect ( Thoenen and Sendtner, 2002 ).”
BackgroundExperimental strategies to promote spinal cord regeneration—an integrative perspective
Schwab, J. M., Brechtel, K., Mueller, C.-A., Failli, V., Kaps, H.-P., Tuli, S. K., & Schluesener, H. J. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.12.004 · Cited by 208
A Sensitized IGF1 Treatment Restores Corticospinal Axon-Dependent Functions
Liu, Y., Wang, X., Li, W., Zhang, Q., Li, Y., Zhang, Z., Zhu, J., Chen, B., Williams, P. R., Zhang, Y., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.037 · Cited by 203
“of neurotrophins and other growth factors in promoting neuronal survival in young and cultured neurons, these factors have limited efficacy in protecting neurons in disease models such as ALS (Thoenen and Sendtner, 2002).”
InfluentialMadduri, S., Papaloïzos, M., & Gander, B. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.073 · Cited by 196
“NTFs support neuronal survival and axonal elongation [15].”
Liu, C., Chan, C. B., & Ye, K. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-015-0048-7 · Cited by 195
“recombinant BDNF are disappointing [15, 16], possibly because of the poor delivery and short in vivo half-life of”
BackgroundImproving peripheral nerve regeneration: From molecular mechanisms to potential therapeutic targets
Chan, K. M., Gordon, T., Zochodne, D. W., & Power, H. A. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.006 · Cited by 189
Schwann cell delivery of neurotrophic factors for peripheral nerve regeneration
Madduri, S., & Gander, B. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00257.x · Cited by 177
“NTFs support neuronal survival and axonal elongation by enhancing the intrinsic regenerative capacity through activation of specific signalling cascades after receptormediated retrograde uptake (Lewin and Barde, 1996; Zurn et al., 1996; Fu and Gordon, 1997; Baloh et al., 2000; Thoenen and Sendtner, 2002; Price et al.,…”
BackgroundThe role of growth factors in diabetic peripheral neuropathy
Leinninger, G. M., Vincent, A. M., & Feldman, E. L. (2004) · Journal of the Peripheral Nervous System · doi:10.1111/j.1085-9489.2004.09105.x · Cited by 170
“Thus, the early positive results of viral vector delivery of growth factors and the outcome of the current VEGF study may demonstrate alternative methods for more efficacious dose delivery, and thus, potential enhancement of growth factor effects (Thoenen and Sendtner, 2002).”
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease
Ries, V., Henchcliffe, C., Kareva, T., Rzhetskaya, M., Bland, R., During, M. J., Kholodilov, N., & Burke, R. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606401103 · Cited by 168
Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS
Alcalá-Barraza, S. R., Lee, M. S., Hanson, L. R., McDonald, A. A., Frey, W. H., & McLoon, L. K. (2010) · Journal of Drug Targeting · doi:10.3109/10611860903318134 · Cited by 164
“Clinical trials have demonstrated that systemic delivery at doses that are sufficiently high to result in therapeutic levels within the CNS parenchyma also result in significant systemic side-effects (Thoenen & Sendtner, 2002).”
BackgroundResultEnriched environment and acceleration of visual system development
Sale, A., Putignano, E., Cancedda, L., Landi, S., Cirulli, F., Berardi, N., & Maffei, L. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.008 · Cited by 163
“In the adult, exposure to enriched environment has protective effects against neurodegeneration that have been demonstrated to be mediated by IGF-I induced BDNF expression (Carro et al., 2000; Thoenen and Sendtner, 2002), but it is not known whether this is also true for the developing brain.”
BackgroundExogenous gangliosides, neuronal plasticity and repair, and the neurotrophins
Mocchetti, I. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5188-y · Cited by 160
Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Mitra, S., Behbahani, H., & Eriksdotter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00038 · Cited by 159
The value of animal models for drug development in multiple sclerosis
Friese, M. A. (2006) · Brain · doi:10.1093/brain/awl083 · Cited by 158
“These proteins regulate survival and differentiation of neurons by binding to specific neurotrophin receptors (Thoenen and Sendtner, 2002).”
BackgroundNeuro-immune crosstalk in CNS diseases
Kerschensteiner, M., Meinl, E., & Hohlfeld, R. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.009 · Cited by 179
“…survival, neurotrophic factors regulate a host of neuronal and glial cell activities, including axonal and dendritic growth, synaptic structure and plasticity, neurotransmitter expression, and long-term potentiation (Lewin and Barde 1996 ; Thoenen and Sendtner 2002 ; Nagappan et al. 2008) .”
Ciliary Neurotrophic Factor Mediates Dopamine D2Receptor-Induced CNS Neurogenesis in Adult Mice
Yang, P., Arnold, S. A., Habas, A., Hetman, M., & Hagg, T. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3574-07.2008 · Cited by 156
“Identifying the molecular mechanisms regulating CNTF expression in vivo and their pharmacological modulators is important, because CNTF is neuroprotective (Hagg and Varon, 1993; Thoenen and Sendtner, 2002) and enhances adult CNS neurogenesis (Emsley and Hagg, 2003).”
BackgroundParadiso, B., Marconi, P., Zucchini, S., Berto, E., Binaschi, A., Bozac, A., Buzzi, A., Mazzuferi, M., Magri, E., Mora, G. N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810710106 · Cited by 155
“We used replication-defective herpes simplex virus–1 (HSV-1) vectors, for multiple reasons (11): they efficiently infect nonreplicating cells such as neurons; they can accommodate large inserts; they do not integrate their genome into the host DNA (that is, there is no mutagenesis risk); they can be transported retrog…”
MethodRemodeling of Axonal Connections Contributes to Recovery in an Animal Model of Multiple Sclerosis
Kerschensteiner, M., Bareyre, F. M., Buddeberg, B. S., Merkler, D., Stadelmann, C., Brück, W., Misgeld, T., & Schwab, M. E. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040452 · Cited by 146
“Growth-promoting therapies might help reestablish axonal connections, either by promoting sprouting or by disinhibiting endogenous growth restriction (33, 39, 40).”
BackgroundGarcia, P., Youssef, I., Utvik, J. K., Florent-Béchard, S., Barthélémy, V., Malaplate-Armand, C., Kriem, B., Stenger, C., Koziel, V., Olivier, J.-L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4182-09.2010 · Cited by 139
“Although potent effects with several NTFs have been reported in animal models, clinical studies did not keep up the promise, most likely because of poor delivery of the therapeutic factor to the site of interest (Thoenen and Sendtner, 2002).”
Deinhardt, K., & Chao, M. V. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-45106-5_5 · Cited by 147
Cho, S.-R., Benraiss, A., Chmielnicki, E., Samdani, A., Economides, A., & Goldman, S. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31778 · Cited by 138
Pilakka-Kanthikeel, S., Atluri, V. S. R., Sagar, V., Saxena, S. K., & Nair, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062241 · Cited by 135
“Clinical trials have demonstrated that systemic deliveries at doses that are sufficiently high to result in therapeutic levels within the CNS parenchyma also result in significant systemic side-effects [49].”
BackgroundTRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson’s disease via CNTF
Nam, J. H., Park, E. S., Won, S.-Y., Lee, Y. A., Kim, K. I., Jeong, J. Y., Baek, J. Y., Cho, E. J., Jin, M., Chung, Y. C., et al. (2015) · Brain · doi:10.1093/brain/awv297 · Cited by 134
Chronic Elevation of Brain-Derived Neurotrophic Factor by Ampakines
Lauterborn, J. C., Truong, G. S., Baudry, M., Bi, X., LYNCH, G. S., & Gall, C. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.053694 · Cited by 138
“Treatment with exogenous BDNF can protect forebrain neurons from hypoglycemic, ischemic, free radical, and other insults in vitro and in vivo (Lindvall et al., 1994; Thoenen and Sendtner, 2002).”
BackgroundBurbach, G. J., Hellweg, R., Haas, C. A., Del Turco, D., Deicke, U., Abramowski, D., Jucker, M., Staufenbiel, M., & Deller, T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5599-03.2004 · Cited by 132
“, 1999), has raised considerable interest in BDNF as a potential therapeutic agent for neurodegenerative disorders (Thoenen and Sendtner, 2002).”
Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease
Fumagalli, F., Racagni, G., & Riva, M. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500360 · Cited by 150
Balaratnasingam, S., & Janča, A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.006 · Cited by 148
Elevating Growth Factor Responsiveness and Axon Regeneration by Modulating Presynaptic Inputs
Zhang, Y., Williams, P. R., Jacobi, A., Wang, C., Goel, A., Hirano, A. A., Brecha, N. C., Kerschensteiner, D., & He, Z. (2019) · Neuron · doi:10.1016/j.neuron.2019.04.033 · Cited by 128
“Attempts to regenerate damaged and diseased axons using neurotrophic growth factors have been primarily unsuccessful (Thoenen and Sendtner, 2002).”
Treatment of chronic low back pain – new approaches on the horizon
Knežević, N. N., Mandalia, S., Raasch, J., Knezevic, I., & Candido, K. D. (2017) · Journal of Pain Research · doi:10.2147/jpr.s132769 · Cited by 131
“While GFs appear to show promise, nerve growth factor (NGF) and glial cell line-derived neurotropic factor (GDNF) produce adverse effects such as pain, bowel urgency, and paraesthesias.(55) Artemin on the other hand is a neurotrophic GF that signals through the GDNF family receptor GFR alpha3 selectively, which is hig…”
BackgroundTejeda, G., & Díaz-Guerra, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020268 · Cited by 126
“These failures have been attributed to the multimodal nature of disease progression, poor neurotrophin delivery to appropriate targets due to limited blood–brain barrier (BBB) permeability and tissue diffusion, short serum half-lives and side effects [3].”
BackgroundGold, S. M., Chalifoux, S., Giesser, B. S., & Voskuhl, R. R. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-32 · Cited by 121
“Conclusion Previously, clinical trials using neurotrophic factors have been disappointing in neurodegenerative diseases despite promising results from pre-clinical studies [40].”
Wiese, S., Jablonka, S., Holtmann, B., Orel, N., Rajagopal, R., Chao, M. V., & Sendtner, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705267104 · Cited by 117
Self-citationLau, D., Bengtson, C. P., Buchthal, B., & Bading, H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.038 · Cited by 116
Hendriks, W. T. J., Ruitenberg, M. J., Blits, B., Boer, G. J., & Verhaagen, J. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46029-9 · Cited by 123
Dual role of inflammation in CNS disease
Hohlfeld, R., Kerschensteiner, M., & Meinl, E. (2007) · Neurology · doi:10.1212/01.wnl.0000275234.43506.9b · Cited by 112
A Novel Endocytic Recycling Signal Distinguishes Biological Responses of Trk Neurotrophin Receptors
Chen, Z.-Y., Ieraci, A., Tanowitz, M., & Lee, F. S. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-07-0651 · Cited by 98
“In previous clinical trials, prolonged systemic BDNF treatment of ALS patients was shown to lead to limitation of the supportive actions of BDNF possibly due to a down-regulation of TrkB receptors (Thoenen, 2001; Thoenen and Sendtner, 2002).”
BackgroundInfluentialWu, C.-H., Hung, T.-H., Chen, C.-C., Ke, C.-H., Lee, C.-Y., Wang, P.-Y., & Chen, S.-F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113397 · Cited by 108
“However, recombinant BDNF has so far yielded disappointing results in clinical trials [13], possibly because of its short plasma half-life and poor blood-brain barrier (BBB) penetration [14].”
BackgroundGelle, T., Samey, R. A., Plansont, B., Bessette, B., Jauberteau-Marchan, M.-O., Lalloué, F., & Girard, M. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110229 · Cited by 109
Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection
Neuhaus, O., Archelos, J. J., & Hartung, H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00028-2 · Cited by 111
Kim, S. R., Kareva, T., Yarygina, O., Kholodilov, N., & Burke, R. E. (2012) · Molecular Therapy · doi:10.1038/mt.2011.213 · Cited by 107
Neurotrophins as Mediators of Drug Effects on Mood, Addiction, and Neuroprotection
Ċastrén, E. (2004) · Molecular Neurobiology · doi:10.1385/mn:29:3:289 · Cited by 119
“The outcome of the clinical trials in which various neurotrophic factors have been tested for different neurodegenerative disorders have been disappointing (1,4).”
BackgroundNeurotrophins as regulators of urinary bladder function
Ochodnický, P., Cruz, C. D., Yoshimura, N., & Cruz, F. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.178 · Cited by 115
Edelbrock, A. N., Àlvarez, Z., Simkin, D., Fyrner, T., Chin, S. M., Sato, K., Kiskinis, E., & Stupp, S. I. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02317 · Cited by 103
Neurotrophic factors in Huntington's disease
Alberch, J., Pérez‐Navarro, E., & Canals, J. M. (2004) · Progress in brain research · doi:10.1016/s0079-6123(03)46014-7 · Cited by 119
VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease
Lambrechts, D., & Carmeliet, P. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.04.005 · Cited by 114
Deoxygedunin, a Natural Product with Potent Neurotrophic Activity in Mice
Jang, S.-W., Liu, X., Chan, C. B., France, S. A., Sayeed, I., Tang, W., Lin, X., Xiao, G., Andero, R., Chang, Q., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011528 · Cited by 101
“disappointing [13,14].”
Stress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 110
“Does the peripherally administered BDNF penetrate into the brain, and to what extent is this a debatable question [202,203]? In addition, if BDNF crosses the BBB by itself or with the help of carriers, an indiscriminate and uncontrolled increase in BDNF levels in the brain may initiate serious side effects, for exampl…”
BackgroundWang, R., King, T. E., Ossipov, M. H., Rossomando, A. J., Vanderah, T. W., Harvey, P. A., Cariani, P., Frank, E., Sah, D. W. Y., & Porreca, F. (2008) · Nature Neuroscience · doi:10.1038/nn2069 · Cited by 98
“These techniques present a considerably greater challenge for translation into clinical practice than that presented by systemic administratio”
BackgroundAngels and demons: neurotrophic factors and epilepsy
Simonato, M., Tongiorgi, E., & Kokaia, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.002 · Cited by 104
Pisati, F., Bossolasco, P., Meregalli, M., Cova, L., Belicchi, M., Gavina, M., Marchesi, C., Calzarossa, C., Soligo, D. A., Lambertenghi‐Deliliers, G., et al. (2007) · Cell Transplantation · doi:10.3727/000000007783464443 · Cited by 102
Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease
Oh, S., Chang, M., Song, J., Rhee, Y., Joe, E.-H., Lee, H., Yi, S., & Lee, S. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404610 · Cited by 108
“Even local administration of trophic factors directly to the vicinity of the desired site appeared to give discouraging outcomes due to inefficient diffusion to the target site (Thoenen & Sendtner, 2002; Sherer et al, 2006).”
Axonal transport and neuronal transcytosis of trophic factors, tracers, and pathogens
von Bartheld, C. S. (2004) · Journal of Neurobiology · doi:10.1002/neu.10315 · Cited by 95
The short-time structural plasticity of dendritic spines is altered in a model of Rett syndrome
Landi, S., Putignano, E., Boggio, E. M., Giustetto, M., Pizzorusso, T., & Ratto, G. M. (2011) · Scientific Reports · doi:10.1038/srep00045 · Cited by 91
Small-molecule trkB agonists promote axon regeneration in cut peripheral nerves
English, A. W., Liu, K., Nicolini, J. M., Mulligan, A. M., & Ye, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303646110 · Cited by 91
“When it has been used experimentally, it has been given in very large doses (15), which is both expensive and runs the risk of untoward side effects or toxicities (16).”
BackgroundYanpallewar, S. U., Barrick, C. A., Buckley, H., Becker, J., & Tessarollo, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039946 · Cited by 90
“However, in clinical trials BDNF has failed to show any beneficial effect [reviewed in [22]].”
BackgroundDietary Polyphenols: A Multifactorial Strategy to Target Alzheimer’s Disease
Dhakal, S., Kushairi, N., Phan, C., Adhikari, B., Sabaratnam, V., & Macreadie, I. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205090 · Cited by 96
Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy
Mazzaro, N., Barini, E., Spillantini, M. G., Goedert, M., Medini, P., & Gasparini, L. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0774-15.2016 · Cited by 94
“From the therapeutic perspective, clinical trials using BDNF have been conducted in neurodegenerative disorders, such as amyotrophic lateral sclerosis and diabetic neuropathy, with inconclusive results (Ochs et al., 2000; Thoenen and Sendtner, 2002).”
Dutta, R., McDonough, J. A., Chang, A., Swamy, L., Siu, A., Kidd, G. J., Rudick, R. A., Mirnics, K., & Trapp, B. D. (2007) · Brain · doi:10.1093/brain/awm206 · Cited by 87
“…factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and glial-derived neuro- trophic factor (GDNF) [reviewed in (Thoenen and Sendtner, 2002; Chao, 2003; Hohlfeld et al., 2006)], we compared by RT-PCR levels of the mRNAs which encode these neurotrophic…”
BackgroundFarokhi, M., Mottaghitalab, F., Shokrgozar, M. A., Kaplan, D. L., Kim, H., & Kundu, S. C. (2016) · International Materials Reviews · doi:10.1080/09506608.2016.1252551 · Cited by 86
Neurotrophin and Trk-mediated Signaling in the Neuromuscular System
Pitts, E. V., Potluri, S., Hess, D. M., & Balice-Gordon, R. J. (2006) · International Anesthesiology Clinics · doi:10.1097/00004311-200604420-00004 · Cited by 82
Faustino, C. M. C., Rijo, P. M., & Reis, C. P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.020 · Cited by 87
Carlsson, T., Schindler, F. R., Höllerhage, M., Depboylu, C., Arias‐Carrión, O., Schnurrbusch, S., Rösler, T. W., Wozny, W., Schwall, G. P., Groebe, K., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07284.x · Cited by 79
“Similar limitations also apply to other known neurotrophic factors (Thoenen and Sendtner 2002).”
BackgroundThe Role of BDNF on Aging-Modulation Markers
Molinari, C. G., Morsanuto, V., Ruga, S., Notte, F., Farghali, M., Galla, R., & Uberti, F. (2020) · Brain Sciences · doi:10.3390/brainsci10050285 · Cited by 88
“Other studies have reported further problems related to the administration of neurotrophins in humans, depending on the dose and pharmacokinetics of these molecules [19].”
BackgroundSmall-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury
Kopp, M. A., Liebscher, T., Niedeggen, A., Laufer, S., Brommer, B., Jungehulsing, G. J., Strittmatter, S. M., Dirnagl, U., & Schwab, J. M. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1334-7 · Cited by 84
“In some of the clinical investigations of neurotrophins in patients with degenerative diseases of the CNS, radicular pain and headache are reported as side effects (Thoenen and Sendtner 2002).”
Enhanced Auditory Neuron Survival Following Cell-Based BDNF Treatment in the Deaf Guinea Pig
Pettingill, L. N., Wise, A. K., Geaney, M. S., & Shepherd, R. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018733 · Cited by 83
“also elicit changes in ion channel properties and neurotransmitter release, and are important in modulating activity-dependent neuronal plasticity that is essential for the functional and structural refinement of neuronal circuits [60,61].”
BackgroundMariga, A., Mitre, M., & Chao, M. V. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.009 · Cited by 83
Fan, X., Zhao, Z., Gu, Y., Han, J., Ye, K., & Zhang, Y. (2021) · eLife · doi:10.7554/elife.64872 · Cited by 79
Capsoni, S., Marinelli, S., Ceci, M., Vignone, D., Amato, G., Malerba, F., Paoletti, F., Meli, G., Viegi, A., Pavone, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037555 · Cited by 74
“diseases remains a considerable challenge [9], due to limited access”
BackgroundAberrant Neuregulin 1 Signaling in Amyotrophic Lateral Sclerosis
Song, F., Chiang, P., Wang, J., Ravits, J., & Loeb, J. A. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182423c43 · Cited by 87
“Polymerase chain reaction was performed in triplicate using 1 TaqMan Universal PCR Master Mix (Applied Biosystems) with the DNA Engine Opticon Continuous Fluorescence Detection System (MJ Research, Waltham, MA) using the following primers and TaqMan probes: Type I NRG1: Mm00626552_m1; Type III NRG1: Mm01212129_m1; BDN…”
BackgroundInfluentialIntranasal delivery of therapeutic proteins for neurological diseases
Malerba, F., Paoletti, F., Capsoni, S., & Cattaneo, A. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.588204 · Cited by 73
“BDNF has also potent neurotrophic survival actions on motoneurons, both in physiological situations and in pathology models, which raised hopes that BDNF could be used for the treatment of neurodegenerative disorders specifically affecting motoneurons, such as ALS [1].”
BackgroundInfluentialLim, C. S., & Alkon, D. L. (2012) · Hippocampus · doi:10.1002/hipo.22048 · Cited by 73
“…have been carried out in the past decade; however, in vivo delivery of NTFs has minimal beneficial effects, produces side effects such as pain and gastrointestinal symptoms, and the purified proteins have uncertain pharmacokinetic profiles (Skaper and Walsh, 1998; Thoenen and Sendtner, 2002).”
BackgroundProspects for mTOR-mediated functional repair after central nervous system trauma
Berry, M., Ahmed, Z., Morgan-Warren, P. J., Fulton, D. J., & Logan, A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.10.002 · Cited by 71
“, 2012) and clinical studies (Thoenen and Sendtner, 2002), but the discovery that subtypes within phenotypic groups of neurons may require particular combinations of growth factors to stimulate axon regeneration (Duan et al.”
BackgroundEsumi, T., Makado, G., Zhai, H., Shimizu, Y., Mitsumoto, Y., & Fukuyama, Y. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.067 · Cited by 69
Sebastião, A. M., & Ribeiro, J. A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00157.x · Cited by 66
Johnson, E. O., Charchanti, A. V., & Soucacos, P. N. (2008) · Injury · doi:10.1016/j.injury.2008.06.015 · Cited by 68
Differential effects of BDNF and neurotrophin 4 ( NT 4) on endocytic sorting of TrkB receptors
Proenca, C. C., Song, M., & Lee, F. S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13676 · Cited by 74
“Our studies suggest that NT4 may be the preferable TrkB ligand as there would be less down-regulation of TrkB receptors with prolonged systemic treatments, as has been implicated for BDNF in previous clinical trials (Thoenen and Sendtner, 2002).”
ResultNie, S., Yan, X., Chen, G., Ma, K., Han, C., Guo, Z., Zhang, Z., Ye, K., & Cao, X. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.08.016 · Cited by 69
The Loop Diuretic Bumetanide Blocks Posttraumatic p75NTRUpregulation and Rescues Injured Neurons
Shulga, A., Magalhães, A. C., Autio, H., Plantman, S., Lieto, A. D., Nykjær, A., Carlstedt, T. P., Risling, M., Arumäe, U., Ċastrén, E., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3282-11.2012 · Cited by 70
“However, supplying the affected neurons with this trophic factor in vivo has proven to be technically extremely challenging (Thoenen and Sendtner, 2002), and novel strategies are needed to circumvent this problem.”
Background
Metadata
- Authors
- Thoenen, H., & Sendtner, M.
- Affiliations
- Max Planck Society (DE)
- University of Würzburg (DE)
- ORCID
- Sendtner, Michael
- Venue
- Nature Neuroscience
- Published
- 2002-10-28
- Volume
- 5
- Issue
- S11
- Pages
- 1046-1050
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2058026578
- Cited by
- 336
- References
- 56
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 19 · 2018: 9 · 2017: 11 · 2016: 20 · 2015: 14 · 2014: 10 · 2013: 17 · 2012: 17
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- neurotrophins, neurotrophic factors, clinical trials, treatment failure, neurotrophin receptors, signal transduction, gene therapy
- MeSH terms
- Animals, Central Nervous System Diseases, Clinical Trials as Topic, Drug Evaluation, Drug Industry, Humans, Nerve Growth Factors, Peripheral Nervous System Diseases, Drug Design, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.